News & Updates

Show Multimedia Only

BP medication timing: Bedtime or daytime, the effect’s the same

27 May 2025 by

For adults with hypertension being treated in the primary care setting, taking their blood pressure (BP)-lowering medications at bedtime is safe but confers no additional cardiovascular protection as opposed to taking them in the morning, according to the results of the BedMed trial.

BP medication timing: Bedtime or daytime, the effect’s the same

27 May 2025

Women with past hypertensive pregnancy at greater CV risk

27 May 2025

Blood pressure values and ventricular mass tend to be more elevated among women with previous de novo pre-eclampsia (PE) than those with previous normal pregnancies, according to a study.

Women with past hypertensive pregnancy at greater CV risk

27 May 2025

Monitor kidney function to reduce CV risk in CKD patients: study

26 May 2025

In patients with stable chronic kidney disease (CKD), the risk of cardiomyopathy caused by kidney disease appears to be greater than the risk of CKD progression due to heart disease, suggests a study, noting that these observational analyses do not establish causality.

Monitor kidney function to reduce CV risk in CKD patients: study

26 May 2025

HF hospitalization risk greater in IMID patients

24 May 2025

Patients with immune-mediated inflammatory disease (IMID) are at increased risk of hospitalization for heart failure (HF) when compared to the general population, reveals a study.

HF hospitalization risk greater in IMID patients

24 May 2025

Cardiac myosin inhibitors: Game-changers in obstructive hypertrophic cardiomyopathy management

24 May 2025 by

Cardiac myosin inhibitors (CMIs) for obstructive hypertrophic cardiomyopathy (HCM) offer effective treatment targeting the underlying pathophysiology of the disease and are recommended as a second-line (2L) option in latest international guidelines. At the 10^th Asian Preventive Cardiology & Cardiac Rehabilitation Conference, Dr Raymond H Chan of the Hypertrophic Cardiomyopathy Clinic, University Health Network, Peter Munk Cardiac Center in Toronto, Canada, discussed why CMIs are game-changers in HCM management and presented a patient case illustrating real-world benefits of the first-in-class CMI, mavacamten.

Cardiac myosin inhibitors: Game-changers in obstructive hypertrophic cardiomyopathy management

24 May 2025

Ageing-related diseases occur early among childhood cancer survivors

23 May 2025

Survivors of childhood cancer undergo accelerated ageing, with a recent study showing a 2-decade earlier onset and a greater lifetime risk of common and life-threatening chronic health conditions (CHCs).

Ageing-related diseases occur early among childhood cancer survivors

23 May 2025

Replacing UPFs with whole foods helps lower BP in children

22 May 2025 by

The consumption of ultraprocessed foods (UPFs) is high among preschool-age children, which can lead to an increase in their diastolic blood pressure (DBP), a study in Canada has shown.

Replacing UPFs with whole foods helps lower BP in children

22 May 2025

Optimizing LDL-C control with nonstatin oral therapy in high CV risk patients

22 May 2025 by

Inadequate control of cardiovascular (CV) risk factors, particularly hypercholesterolaemia, continues to drive high global mortality rates from CV disease (CVD). At a recent industry-sponsored meeting, Dr Carlos Escobar Cervantes from La Paz University Hospital, Spain, discussed major barriers to achieving optimal LDL-cholesterol (LDL-C) control, while Professor Ioanna Gouni-Berthold from the University of Cologne, Germany, shared insights and real-world evidence on CV risk reduction with bempedoic acid.

Optimizing LDL-C control with nonstatin oral therapy in high CV risk patients

22 May 2025

Apixaban a safe oral anticoagulant choice for VTE patients

22 May 2025

For patients with venous thromboembolism (VTE) who are initiating an oral anticoagulant, apixaban use appears to be safer than rivaroxaban and warfarin, with lower risks of VTE recurrence and major bleeding, as reported in a study.

Apixaban a safe oral anticoagulant choice for VTE patients

22 May 2025

Mild low birthweight carries increased childhood hypertension risk

21 May 2025 by

Children born with mild low birthweight (LBW) are at increased risk of hypertension, according to new research.

Mild low birthweight carries increased childhood hypertension risk

21 May 2025

News & Updates

Filter by Specialty:

Specialty:

BP medication timing: Bedtime or daytime, the effect’s the same

BP medication timing: Bedtime or daytime, the effect’s the same

Women with past hypertensive pregnancy at greater CV risk

Women with past hypertensive pregnancy at greater CV risk

Monitor kidney function to reduce CV risk in CKD patients: study

Monitor kidney function to reduce CV risk in CKD patients: study

HF hospitalization risk greater in IMID patients

HF hospitalization risk greater in IMID patients

Cardiac myosin inhibitors: Game-changers in obstructive hypertrophic cardiomyopathy management

Cardiac myosin inhibitors: Game-changers in obstructive hypertrophic cardiomyopathy management

Ageing-related diseases occur early among childhood cancer survivors

Ageing-related diseases occur early among childhood cancer survivors

Replacing UPFs with whole foods helps lower BP in children

Replacing UPFs with whole foods helps lower BP in children

Optimizing LDL-C control with nonstatin oral therapy in high CV risk patients

Optimizing LDL-C control with nonstatin oral therapy in high CV risk patients

Apixaban a safe oral anticoagulant choice for VTE patients

Apixaban a safe oral anticoagulant choice for VTE patients

Mild low birthweight carries increased childhood hypertension risk

Mild low birthweight carries increased childhood hypertension risk